News Bold Therapeutics Presents Late-Breaking Poster on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025April 30, 2025 Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)April 29, 2025 Gaston Capital Promotes Kyle Radavich to Senior AssociateMarch 13, 2025 Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 ‘Metals in Medicine’ Gordon Research ConferenceJune 27, 2024 Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024June 3, 2024 Gaston Capital Announces New AssociateApril 15, 2024 BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024April 5, 2024 Gaston Capital Names Walthall New Managing PartnerApril 1, 2024 Enviro-Master Services Launches Transformative Enviro-Safe AppMarch 7, 2024 Freemotion Fitness and Aktiv Solutions Forge a Transformative Strategic AllianceFebruary 24, 2024 Aktiv Solutions Unveils the Evolutionary SMITH 3D TrainerFebruary 14, 2024 Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024January 22, 2024 Load More News
Bold Therapeutics Presents Late-Breaking Poster on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025April 30, 2025
Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100’s Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)April 29, 2025
Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 ‘Metals in Medicine’ Gordon Research ConferenceJune 27, 2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024June 3, 2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024January 22, 2024
